EC
INDV icon

Elequin Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Elequin Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410 Sell
10
-7
-41% -$254 ﹤0.01% 615
2026
Q1 		$518 Buy
+17
New +$561 ﹤0.01% 574

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elequin Capital's INDV Position: Q2 2026 in Review

Elequin Capital reduced its Indivior Pharmaceuticals (INDV) stake by 41% in Q2 2026, selling an estimated $254 and leaving 10 shares worth $410. The position accounts for ﹤0.01% of the portfolio, ranked #615.

Elequin Capital first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. The position peaked at $518 in Q1 2026. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Elequin Capital held 10 shares of Indivior Pharmaceuticals worth $410 as of Q2 2026.
  • Elequin Capital sold 7 Indivior Pharmaceuticals shares in Q2 2026, an estimated $254.
  • Indivior Pharmaceuticals made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #615 holding.
  • Elequin Capital first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Elequin Capital's Indivior Pharmaceuticals position peaked at $518 in Q1 2026.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.